Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy
Shannon N. Geels, A. Moshensky, Rachel S. Sousa, et al.
Cancer Cell (2024) Vol. 42, Iss. 6, pp. 1051-1066.e7
Closed Access | Times Cited: 21

Showing 21 citing articles:

Platycodon grandiflorum-derived extracellular vesicles suppress triple-negative breast cancer growth by reversing the immunosuppressive tumor microenvironment and modulating the gut microbiota
Min Yang, Jia Guo, Jinxian Li, et al.
Journal of Nanobiotechnology (2025) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Regulatory T cells in immune checkpoint blockade antitumor therapy
An Zhang, Tao Fan, Yixiao Liu, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 14
CD8+ T cell exhaustion and its regulatory mechanisms in the tumor microenvironment: key to the success of immunotherapy
Biao Zhang, Jinming Liu, Yuying Mo, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Jun, an Oncological Foe or Friend?
Zuhayr Jafri, Yue Li, Jingwen Zhang, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 555-555
Open Access
Resistance mechanisms to immune checkpoint inhibitors: updated insights
Besan H. Al-Saafeen, Bassam R. Ali, Eyad Elkord
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
Exploring prognosis and therapeutic strategies for HBV-HCC patients based on disulfidptosis-related genes
Chunyu Zhang, Xing Zhang, Shengjie Dai, et al.
Frontiers in Genetics (2025) Vol. 15
Open Access
Multifunctional nanozymes for sonodynamic-enhanced immune checkpoint blockade therapy by inactivating PI3K/AKT signal pathway
Mei Wen, Pu Qiu, Jialan Meng, et al.
Biomaterials (2025), pp. 123125-123125
Closed Access
Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab
Yuta Myojin, Sepideh Babaei, Rajiv Trehan, et al.
Gut (2025), pp. gutjnl-334026
Closed Access
PRTN3 promotes IL33/Treg-mediated tumor immunosuppression by enhancing the M2 polarization of tumor-associated macrophages in lung adenocarcinoma
Jiayu Jiang, H. Chen, Chunxing Zhao, et al.
Cancer Letters (2025), pp. 217584-217584
Closed Access
Exploring the “chemo” in chemoimmunotherapy for triple-negative breast cancer
Ting Liu, Leif W. Ellisen
Cancer Cell (2025) Vol. 43, Iss. 3, pp. 332-334
Closed Access
Targeting novel immune checkpoints in the B7-H family: advancing cancer immunotherapy from bench to bedside
Yiming Luo, Ye Yuan, Shilin Liu, et al.
Trends in cancer (2025)
Open Access
A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer
Zedao Liu, Zhenlin Yang, Junqi Wu, et al.
Cell (2025)
Open Access
CD8+ T Cell Subsets as Biomarkers for Predicting Checkpoint Therapy Outcomes in Cancer Immunotherapy
Rosaely Casalegno‐Garduño, Alf Spitschak, Tim Pannek, et al.
Biomedicines (2025) Vol. 13, Iss. 4, pp. 930-930
Open Access
ICOS and ICOS ligand: expression patterns and outcomes in oncology patients
Mina Nikanjam, Shumei Kato, Daisuke Nishizaki, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders
X Li, Yuanxin Liu, Jun Gui, et al.
Advanced Science (2024) Vol. 11, Iss. 41
Open Access | Times Cited: 3
Turning cold into hot: emerging strategies to fire up the tumor microenvironment
Kejing Ma, Lin Wang, Wenhui Li, et al.
Trends in cancer (2024)
Closed Access | Times Cited: 3
Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma
Weifeng Zeng, Furong Liu, Yachong Liu, et al.
Clinical and Molecular Hepatology (2024)
Open Access | Times Cited: 2
Discovery of Novel 5-(Pyridazin-3-yl)pyrimidine-2,4(1H,3H)-dione Derivatives as Potent and Orally Bioavailable Inhibitors Targeting Ecto-5′-nucleotidase
Yu Xu, Dan Liu, Wenzhuang Zhang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 20, pp. 18491-18511
Closed Access | Times Cited: 1
Breaking up the CD8+ T cell: Treg pas de deux
Chen‐Yu Zhang, Alissa Bockman, Michel DuPage
Cancer Cell (2024) Vol. 42, Iss. 6, pp. 941-942
Closed Access
Protocol to quantify the activation dynamics of tumor-associated T cells in mice by functional intravital microscopy
Shannon N. Geels, Claire Murat, A. Moshensky, et al.
STAR Protocols (2024) Vol. 5, Iss. 4, pp. 103310-103310
Open Access
Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma
Anum Jalil, Melissa M Donate, Jane Mattei
Cancer Drug Resistance (2024)
Open Access
Association of PD-1 + Treg/PD-1 + CD8 ratio and tertiary lymphoid structures with prognosis and response in advanced gastric cancer patients receiving preoperative treatment
Xu Liu, Danhua Xu, Cheng‐Bei Zhou, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access
Page 1

Scroll to top